The obligation to respect national and most-favoured nation treatment essentially means that LDC Members may not deny IP protection to the citizens of certain Members if they grant the same to their own citizens or to citizens of any other country. See Articles 3-5, TRIPS Agreement. Where an LDC’s IP-related practice (e.g. through continuous jurisprudence) has in the past excluded certain areas of technology from patentability, or applied particularly large exceptions to a particular technology, this LDC may continue such practice, despite the obligations under TRIPS to make patent protection available in all fields of technology, without discrimination between different fields of technology. On the other hand, the same country may not disapply patent protection to areas of technology previously covered by its law.81 While the no-roll-back requirement sets important limitations for LDCs’ industrial policies, it should be emphasized that this limitation does not apply in the area of pharmaceutical products (see below).82 Finally, the 2013 extension does not prevent LDC members from reducing existing domestic “TRIPS-plus” provisions (i.e. going beyond the TRIPS minimum standards) and moving toward TRIPS minimum standards.